中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(12): 2824-2830

Association between spontaneous portosystemic shunt and hepatorenal syndrome in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.12.012

  • Department of Radiology，Dezhou Hospital，Qilu Hospital of Shandong University，Dezhou，Shandong 253000，China

Research funding:

Shandong Provincial Medical and Health Science and Technology Development Project (202109010537)

More Information
  • Corresponding author: XU Wanbo， 18005342388@163.com （ORCID： 0009-0007-5129-9566）
  • Received Date: 2023-02-10
  • Accepted Date: 2023-03-27
  • Published Date: 2023-12-12
    Abstract
  •   Objective  To investigate the association between spontaneous portosystemic shunt （SPSS） and hepatorenal syndrome （HRS） in patients with liver cirrhosis.  Methods  A retrospective analysis was performed for 93 patients with SPSS from Dezhou Hospital， Qilu Hospital of Shandong University， from January 2015 to January 2022， and the patients were followed up for 12 months with the onset of HRS as the observation endpoint. According to the presence or absence of HRS， the 93 patients with SPSS were divided into HRS group with 38 patients （40.86%） and non-HRS group with 55 patients （59.14%）， and the two groups were compared in terms of clinical data， laboratory data， complication， and shunt diameter. Based on the maximum shunt vein diameter of 1.5 cm， the 93 patients with SPSS were divided into high shunt group with 52 patients （55.91%） and low shunt group with 41 patients （44.09%）， and with the onset of HRS as the observation endpoint， the two groups were compared in terms of the incidence rate of HRS and survival time curve. The independent-samples t test was used for comparison of normally distributed continuous data with homogeneity of variance between two groups， and the chi-square test was used for comparison of categorical data between two groups. The receiver operating characteristic （ROC） curve was used to predict cut-off values， the Kaplan-Meier curve was used for comparison of survival time， and the Log-rank test was used to compare the differences in survival curves. The multivariate Cox regression analysis was used to investigate risk factors.  Results  Compared with the non-HRS group， the HRS group had significant increases in Child-Pugh score， Child-Pugh class， MELD score， serum creatinine， blood urea nitrogen， alanine aminotransferase， aspartate aminotransferase， maximum shunt vein diameter， the incidence rates of hepatic encephalopathy and spontaneous bacterial peritonitis， and the degree of ascites， as well as significant reductions in main portal vein diameter， serum sodium and albumin （all P<0.05）. Compared with the low shunt group， the high shunt group had a significant increase in the incidence rate of HRS （51.92% vs 26.83%， χ²=5.974， P=0.015） and a significant reduction in the time to the onset of HRS （Log-rank P=0.033）. A maximum shunt vein diameter of >1.5 cm （hazard ratio ［HR］=1.123， 95% confidence interval ［CI］： 1.041‍ ‍—‍ ‍1.211， P=0.003）， an increase in MELD score （HR=1.205， 95%CI： 1.076‍ ‍—‍ ‍1.437， P=0.039）， a reduction in serum albumin （HR=0.890， 95%CI： 0.814‍ ‍—‍ ‍0.974， P=0.011）， an increase in the degree of ascites （HR=2.099， 95%CI： 1.066‍ ‍—‍ ‍4.130， P=0.032）， and spontaneous bacterial peritonitis （HR=2.259， 95%CI： 1.020‍ ‍—‍ ‍5.003， P=0.045） were independent risk factors for the onset of HRS in SPSS patients.  Conclusion  There is an association between SPSS and HRS， and shunt diameter >1.5 cm was an independent risk factor for HRS in SPSS patients， which should be taken seriously and require early intervention in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    RATHI S, BROCCO S, FORMENTIN C, et al. Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations[J]. Dig Liver Dis, 2021, 53( 11): 1468- 1475. DOI: 10.1016/j.dld.2020.11.020.
    [2]
    AMIN AA, ALABSAWY EI, JALAN R, et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome[J]. Semin Nephrol, 2019, 39( 1): 17- 30. DOI: 10.1016/j.semnephrol.2018.10.002.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [4]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.

    中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33( 10): 1847- 1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
    [5]
    WANG Y, XU Y, SUN W, et al. Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 8): 1774- 1779. DOI: 10.3969/j.issn.1001-5256.2022.08.011.

    王艳, 徐英, 孙蔚, 等. IL-6联合终末期肝病模型评分对HBV相关慢加急性肝衰竭预后的预测价值[J]. 临床肝胆病杂志, 2022, 38( 8): 1774- 1779. DOI: 10.3969/j.issn.1001-5256.2022.08.011.
    [6]
    NARDELLI S, RIGGIO O, TURCO L, et al. Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis[J]. Radiology, 2021, 299( 1): 133- 140. DOI: 10.1148/radiol.2021203051.
    [7]
    LI WG, XU XY. Management of renal injury include hepatorenal syndrome in patients with decompensated liver cirrhosis[J]. Chin J Hepatol, 2020, 28( 5): 381- 385. DOI: 10.3760/cma.j.cn501113-20200427-00216.

    李文刚, 徐小元. 失代偿性肝硬化患者合并肾损伤与肝肾综合征的管理[J]. 中华肝脏病杂志, 2020, 28( 5): 381- 385. DOI: 10.3760/cma.j.cn501113-20200427-00216.
    [8]
    LIANG JQ, LIU W. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatorenal syndrome[J]. J Clin Hepatol, 2022, 38( 9): 1974- 1979. DOI: 10.3969/j.issn.1001-5256.2022.09.005.

    梁家琦, 刘汶. 肝肾综合征的中西医结合诊治[J]. 临床肝胆病杂志, 2022, 38( 9): 1974- 1979. DOI: 10.3969/j.issn.1001-5256.2022.09.005.
    [9]
    YANG LH, YANG JH. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. J Clin Hepatol, 2021, 37( 12): 2770- 2773. DOI: 10.3969/j.issn.1001-5256.2021.12.006.

    杨黎宏, 杨晋辉. 肝肾综合征门体循环失衡的机制与治疗[J]. 临床肝胆病杂志, 2021, 37( 12): 2770- 2773. DOI: 10.3969/j.issn.1001-5256.2021.12.006.
    [10]
    Hepatobiliary Study Group of Chinese Society of Gastroenterology of Chinese Medical Association, Hepatology Committee of Chinese Research Hospital Association. Practice guidance for the use of terlipressin for liver cirrhosis related complications(2021)[J]. J Clin Hepatol, 2022, 38( 8): 1733- 1738. DOI: 10.3969/j.issn.1001-5256.2022.08.006.

    中华医学会消化病学分会肝胆疾病学组, 中国研究型医院学会肝病专业委员会. 特利加压素在肝硬化并发症临床应用的实践指导(2021版)[J]. 临床肝胆病杂志, 2022, 38( 8): 1733- 1738. DOI: 10.3969/j.issn.1001-5256.2022.08.006.
    [11]
    WANG JB. New concept of hepatorenal syndrome[J]. Chin J Dig, 2021, 41( 5): 312- 315. DOI: 10.3760/cma.j.cn311367-20210302-00131.

    王江滨. 肝肾综合征的新概念[J]. 中华消化杂志, 2021, 41( 5): 312- 315. DOI: 10.3760/cma.j.cn311367-20210302-00131.
    [12]
    KAZORY A, RONCO C. Hepatorenal syndrome or hepatocardiorenal syndrome: Revisiting basic concepts in view of emerging data[J]. Cardiorenal Med, 2019, 9( 1): 1- 7. DOI: 10.1159/000492791.
    [13]
    ZHANG XF, HE QJ, WANG HY, et al. An excerpt of report of the Baveno VII Consensus Workshop: Personalized care in portal hypertension[J]. J Clin Hepatol, 2022, 38( 6): 1258- 1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010.

    张晓丰, 何钦俊, 王海玉, 等.《BavenoⅦ门静脉高压共识更新: 门静脉高压的个体化管理》摘译[J]. 临床肝胆病杂志, 2022, 38( 6): 1258- 1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010.
    [14]
    HU JX, HAN T. An excerpt of diagnosis, evaluation, and management of ascites and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. J Clin Hepatol, 2021, 37( 11): 2548- 2549. DOI: 10.3969/j.issn.1001-5256.2021.11.012.

    胡家轩, 韩涛.《2021年美国肝病学会实践指导: 腹水和肝肾综合征的诊断、评估和管理》摘译[J]. 临床肝胆病杂志, 2021, 37( 11): 2548- 2549. DOI: 10.3969/j.issn.1001-5256.2021.11.012.
    [15]
    LIAO XH, YE JZ, ZHONG BH. Pathogenesis of hepatorenal syndrome[J]. J Clin Hepatol, 2020, 36( 11): 2406- 2410. DOI: 10.3969/j.issn.1001-5256.2020.11.002.

    廖献花, 叶俊钊, 钟碧慧. 肝肾综合征的发病机制[J]. 临床肝胆病杂志, 2020, 36( 11): 2406- 2410. DOI: 10.3969/j.issn.1001-5256.2020.11.002.
    [16]
    ZHU BB, YANG JX, ZHANG Q, et al. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. J Clin Hepatol, 2022, 38( 7): 1561- 1565. DOI: 10.3969/j.issn.1001-5256.2022.07.019.

    朱冰冰, 杨晋翔, 张群, 等. 1型肝肾综合征患者90天预后危险因素分析及预测模型构建[J]. 临床肝胆病杂志, 2022, 38( 7): 1561- 1565. DOI: 10.3969/j.issn.1001-5256.2022.07.019.
    [17]
    HAO SS, YAO J, YUAN LL. Analysis of prognostic factors for hepatorenal syndrome in patients with liver cirrhosis[J]. Chin Hepatol, 2021, 26( 2): 151- 154. DOI: 10.14000/j.cnki.issn.1008-1704.2021.02.015.

    郝莎莎, 姚佳, 原丽莉. 肝硬化并发肝肾综合征患者预后影响因素分析[J]. 肝脏, 2021, 26( 2): 151- 154. DOI: 10.14000/j.cnki.issn.1008-1704.2021.02.015.
    [18]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, and Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538.
    [19]
    SHANG YY, XU WT, GUO XZ, et al. Research progress on application of terlipressin in complications of liver cirrhosis[J]. Clin J Med Offic, 2022, 50( 9): 884- 886. DOI: 10.16680/j.1671-3826.2022.09.02.

    商一扬, 许文涛, 郭晓钟, 等. 特利加压素在肝硬化并发症中应用研究进展[J]. 临床军医杂志, 2022, 50( 9): 884- 886. DOI: 10.16680/j.1671-3826.2022.09.02.
    [20]
    ANGELI P, GARCIA-TSAO G, NADIM MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites(ICA) consensus document[J]. J Hepatol, 2019, 71( 4): 811- 822. DOI: 10.1016/j.jhep.2019.07.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (367) PDF downloads(65) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return